Cara Therapeutics reported $-31246000 in EBITDA for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acadia Pharmaceuticals ACAD:US USD -45574000 15.21M
Acelrx Pharmaceuticals ACRX:US USD -6208000 2M
Cara Therapeutics CARA:US USD -31246000 7.46M
Depomed DEPO:US USD 30.93M 12.43M
Endo International Ordinary Shares ENDP:US USD 151.76M 22.28M
Halozyme Therapeutics HALO:US USD 83.06M 29.83M
Horizon Pharma HZNP:US USD 313.74M 26.49M
JAZZ PHA JAZZ:US USD -118655000 466.69M
Johnson & Johnson JNJ:US USD 7.34B 1.2B
Neurocrine Biosciences NBIX:US USD 107.8M 16M
Pacira Pharmaceuticals PCRX:US USD 44.76M 2.79M
Pfizer PFE:US USD 6.94B 3.94B
Revance Therapeutics RVNC:US USD -57156000 14.89M
Supernus Pharmaceuticals SUPN:US USD 55.83M 35.58M
Teva Pharmaceutical Industries TEVA:US USD 1.31B 245M
Vanda Pharmaceuticals VNDA:US USD 7.29M 2.71M